Miller Fisher Syndrome Associated with Parvovirus B19 Infection in a Child

Filippo Greco; Alice Le Pira; Luisa Scalora; Roberta Catania; Tiziana Timpanaro; Pierluigi Smilari; Giovanni Sorge

doi:10.1055/s-0036-1584277

Journal of Pediatric Neurology, Table of Contents

Journal of Pediatric Neurology 2016; 14(02): 075-077
DOI: 10.1055/s-0036-1584277

Case Report

Georg Thieme Verlag KG Stuttgart · New York

Miller Fisher Syndrome Associated with Parvovirus B19 Infection in a Child

Authors

Filippo Greco

¹Unit of Clinical Pediatrics, Department of Medical and Pediatric Sciences, University of Catania, Catania, Italy
Alice Le Pira

¹Unit of Clinical Pediatrics, Department of Medical and Pediatric Sciences, University of Catania, Catania, Italy
Luisa Scalora

¹Unit of Clinical Pediatrics, Department of Medical and Pediatric Sciences, University of Catania, Catania, Italy
Roberta Catania

¹Unit of Clinical Pediatrics, Department of Medical and Pediatric Sciences, University of Catania, Catania, Italy
Tiziana Timpanaro

¹Unit of Clinical Pediatrics, Department of Medical and Pediatric Sciences, University of Catania, Catania, Italy
Pierluigi Smilari

¹Unit of Clinical Pediatrics, Department of Medical and Pediatric Sciences, University of Catania, Catania, Italy
Giovanni Sorge

¹Unit of Clinical Pediatrics, Department of Medical and Pediatric Sciences, University of Catania, Catania, Italy

Abstract

Miller Fisher syndrome (MFS) is a variant of Guillain–Barré syndrome, and it is typically characterized by the triad of ophthalmoplegia, ataxia, and areflexia. We report a 13-year-old boy affected with MFS associated with parvovirus B19 infection in which immunoglobulin (Ig)G and IgM anti-GQ1b antibodies were not detected. Treatment with intravenous Igs resulted in a progressive and rapid resolution of the clinical features. To our knowledge, this is the first example in the literature of seronegative anti-GQ1b antibody MFS associated with parvovirus B19 infection in childhood. The possible role of other gangliosides is discussed.

Keywords

parvovirus B19 - Miller Fisher syndrome - childhood - immunoglobulins

Full Text

References

References
1 Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis 2009; 48 (12) 1713-1723
2 Minohara Y, Koitabashi Y, Kato T , et al. A case of Guillain-Barré syndrome associated with human parvovirus B19 infection. J Infect 1998; 36 (3) 327-328
3 Guidi B, Bergonzini P, Crisi G, Frigieri G, Portolani M. Case of stroke in a 7-year-old male after parvovirus B19 infection. Pediatr Neurol 2003; 28 (1) 69-71
4 Mori M, Kuwabara S, Yuki N. Fisher syndrome: clinical features, immunopathogenesis and management. Expert Rev Neurother 2012; 12 (1) 39-51
5 Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350 (6) 586-597
6 Barah F, Vallely PJ, Cleator GM, Kerr JR. Neurological manifestations of human parvovirus B19 infection. Rev Med Virol 2003; 13 (3) 185-199
7 Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70 (1) 50-55
8 Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 2013; 84 (5) 576-583
9 Terhes G, Jenei M, Bereg E, Túri S, Deák J. Neurologic consequence of a parvovirus B19 infection. J Clin Virol 2013; 56 (2) 156-158
10 Koga M, Gilbert M, Takahashi M , et al. GQ1b-seronegative Fisher syndrome: clinical features and new serological markers. J Neurol 2012; 259 (7) 1366-1374